Erdafitinib - Janssen Pharmaceutica

Drug Profile

Erdafitinib - Janssen Pharmaceutica

Alternative Names: G-024; JNJ-42756493; JNJ-493

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics
  • Developer Genentech; Janssen Research & Development; Multiple Myeloma Research Consortium; National Cancer Institute (USA); University Health Network of Toronto; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Urogenital cancer
  • Phase II Cholangiocarcinoma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer
  • Phase I/II Hepatocellular carcinoma; Lymphoma; Solid tumours
  • Phase I Breast cancer; Cancer

Most Recent Events

  • 15 Mar 2018 Erdafitinib - Janssen Pharmaceutica receives Breakthrough Therapy status for Urogenital cancer (Metastatic disease) in USA
  • 27 Feb 2018 Phase-III clinical trials in Urogenital cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Hungary (PO) (EudraCT2017-002932-18)
  • 23 Jan 2018 Janssen Pharmaceutica announces intention to submit regulatory applications in the US and EU for Urothelial cancer between 2018 - 2021 (Johnson & Johnson pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top